NASDAQ$CABA
Cabaletta Bio Inc · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Reported financial results for Q4 and full year 2022 and provided a business update.
Cabaletta Bio reported its Q4 and full year 2022 financial results, highlighting the expected IND clearance for CABA-201 in the first half of 2023 and potential initial clinical data by the first half of 2024.
- Cabaletta Bio anticipates Investigational New Drug (IND) clearance in the first half of 2023 for CABA-201.
- Initial clinical data for CABA-201 is expected in the first half of 2024.
- The company continues to progress its pipeline of clinical-stage CAART legacy product candidates.
- Cabaletta raised $32.6 million in net proceeds from an oversubscribed offering in December 2022.
Headline financials
Revenue & EPS history
Cabaletta Bio · Revenue · Quarterly
$0
Forward guidance
Cabaletta Bio is focused on advancing its autoimmune-focused pipeline and delivering on multiple upcoming value-creating milestones, with expectations of IND clearance for CABA-201 in the first half of 2023 and initial clinical data anticipated in the first half of 2024.
Tailwinds
- IND clearance expected in the first half of 2023 for CABA-201.
- Initial clinical data anticipated in the first half of 2024.
- Progress in the combination sub-study of DesCAARTes™ trial.
- Initiation of the first-in-human MusCAARTes™ trial.
- Preclinical data supporting IND application and MusCAARTes™ trial design published in Nature Biotechnology.
Headwinds
- Risks related to regulatory filings and potential clearance.
- Risk that signs of biologic activity or persistence may not inform long-term results.
- Risks related to clinical trial site activation or enrollment rates that are lower than expected.
- Risks related to unexpected safety or efficacy data observed during clinical studies.
- Risks related to volatile market and economic conditions.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2022
+2.7%
Avg return
Earnings day
+3.2%
Avg return
5 days after
+5.3%
Avg return
30 days after
67%
16 / 24 earnings
Positive
+22.7%
Q3 2022
Best reaction
-24.4%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -7.8% | -9.0% | -16.2% | |
| Q3 2025 | -5.0% | -9.4% | -5.1% | |
| Q1 2025 | -0.6% | +6.9% | -2.9% | |
| Q4 2024 | +12.8% | -28.4% | -14.8% | |
| Q3 2024 | -24.4% | -36.7% | -29.7% | |
| Q1 2024 | +12.4% | +14.7% | -5.1% | |
| Q4 2023 | -4.2% | -6.4% | -26.4% | |
| Q3 2023 | +4.0% | +1.6% | -5.6% | |
| Q2 2023 | +10.0% | +10.4% | +12.0% | |
| Q1 2023 | +1.6% | +7.0% | -1.2% | |
| Q4 2022 | +9.3% | +4.3% | +5.4% | |
| Q3 2022 | +22.7% | +84.0% | +207.2% | |
| Q2 2022 | +19.5% | +17.2% | -26.3% | |
| Q1 2022 | +21.1% | +52.8% | -3.3% | |
| Q4 2021 | +14.6% | +32.7% | +6.4% | |
| Q3 2021 | +2.4% | -5.3% | -19.1% | |
| Q2 2021 | +2.0% | +1.9% | +58.0% | |
| Q1 2021 | -6.6% | -14.0% | -7.2% | |
| Q4 2020 | +1.7% | -4.0% | -8.7% | |
| Q3 2020 | +6.7% | +7.1% | +19.3% | |
| Q2 2020 | +6.4% | +4.6% | -15.8% | |
| Q1 2020 | -9.3% | -8.0% | -8.0% | |
| Q4 2019 | +0.3% | -7.6% | +10.7% | |
| Q3 2019 | -23.7% | -38.7% | +3.7% | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro